Krabbe disease is an uncommon and typically deadly concern of the nervous system. It is an acquired hereditary sickness, which implies that it is passed down in families. Individuals with Krabbe disease are not able to make a sufficient substance called galactosylceramidase, which is expected to make myelin in a human body.
The global Krabbe Disease Drugs market size is projected to grow from US$ million in 2023 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.
LPI (LP Information)' newest research report, the “Krabbe Disease Drugs Industry Forecast” looks at past sales and reviews total world Krabbe Disease Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Krabbe Disease Drugs sales for 2024 through 2030. With Krabbe Disease Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Krabbe Disease Drugs industry.
This Insight Report provides a comprehensive analysis of the global Krabbe Disease Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Krabbe Disease Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Krabbe Disease Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Krabbe Disease Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Krabbe Disease Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Krabbe Disease Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
Anticonvulsants
Muscle Relaxants
Others
Segmentation by application
Hospitals
Clinics
Research Centers
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Johnson & Johnson
Novartis
Pfizer
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Takeda
UCB Pharmaceuticals

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Krabbe Disease Drugs Market Size 2019-2030 2.1.2 Krabbe Disease Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030 2.2 Krabbe Disease Drugs Segment by Type 2.2.1 Anticonvulsants 2.2.2 Muscle Relaxants 2.2.3 Others 2.3 Krabbe Disease Drugs Market Size by Type 2.3.1 Krabbe Disease Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) 2.3.2 Global Krabbe Disease Drugs Market Size Market Share by Type (2019-2024) 2.4 Krabbe Disease Drugs Segment by Application 2.4.1 Hospitals 2.4.2 Clinics 2.4.3 Research Centers 2.4.4 Others 2.5 Krabbe Disease Drugs Market Size by Application 2.5.1 Krabbe Disease Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) 2.5.2 Global Krabbe Disease Drugs Market Size Market Share by Application (2019-2024) 3 Krabbe Disease Drugs Market Size by Player 3.1 Krabbe Disease Drugs Market Size Market Share by Players 3.1.1 Global Krabbe Disease Drugs Revenue by Players (2019-2024) 3.1.2 Global Krabbe Disease Drugs Revenue Market Share by Players (2019-2024) 3.2 Global Krabbe Disease Drugs Key Players Head office and Products Offered 3.3 Market Concentration Rate Analysis 3.3.1 Competition Landscape Analysis 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024) 3.4 New Products and Potential Entrants 3.5 Mergers & Acquisitions, Expansion 4 Krabbe Disease Drugs by Regions 4.1 Krabbe Disease Drugs Market Size by Regions (2019-2024) 4.2 Americas Krabbe Disease Drugs Market Size Growth (2019-2024) 4.3 APAC Krabbe Disease Drugs Market Size Growth (2019-2024) 4.4 Europe Krabbe Disease Drugs Market Size Growth (2019-2024) 4.5 Middle East & Africa Krabbe Disease Drugs Market Size Growth (2019-2024) 5 Americas 5.1 Americas Krabbe Disease Drugs Market Size by Country (2019-2024) 5.2 Americas Krabbe Disease Drugs Market Size by Type (2019-2024) 5.3 Americas Krabbe Disease Drugs Market Size by Application (2019-2024) 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Krabbe Disease Drugs Market Size by Region (2019-2024) 6.2 APAC Krabbe Disease Drugs Market Size by Type (2019-2024) 6.3 APAC Krabbe Disease Drugs Market Size by Application (2019-2024) 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Krabbe Disease Drugs by Country (2019-2024) 7.2 Europe Krabbe Disease Drugs Market Size by Type (2019-2024) 7.3 Europe Krabbe Disease Drugs Market Size by Application (2019-2024) 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Krabbe Disease Drugs by Region (2019-2024) 8.2 Middle East & Africa Krabbe Disease Drugs Market Size by Type (2019-2024) 8.3 Middle East & Africa Krabbe Disease Drugs Market Size by Application (2019-2024) 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Global Krabbe Disease Drugs Market Forecast 10.1 Global Krabbe Disease Drugs Forecast by Regions (2025-2030) 10.1.1 Global Krabbe Disease Drugs Forecast by Regions (2025-2030) 10.1.2 Americas Krabbe Disease Drugs Forecast 10.1.3 APAC Krabbe Disease Drugs Forecast 10.1.4 Europe Krabbe Disease Drugs Forecast 10.1.5 Middle East & Africa Krabbe Disease Drugs Forecast 10.2 Americas Krabbe Disease Drugs Forecast by Country (2025-2030) 10.2.1 United States Krabbe Disease Drugs Market Forecast 10.2.2 Canada Krabbe Disease Drugs Market Forecast 10.2.3 Mexico Krabbe Disease Drugs Market Forecast 10.2.4 Brazil Krabbe Disease Drugs Market Forecast 10.3 APAC Krabbe Disease Drugs Forecast by Region (2025-2030) 10.3.1 China Krabbe Disease Drugs Market Forecast 10.3.2 Japan Krabbe Disease Drugs Market Forecast 10.3.3 Korea Krabbe Disease Drugs Market Forecast 10.3.4 Southeast Asia Krabbe Disease Drugs Market Forecast 10.3.5 India Krabbe Disease Drugs Market Forecast 10.3.6 Australia Krabbe Disease Drugs Market Forecast 10.4 Europe Krabbe Disease Drugs Forecast by Country (2025-2030) 10.4.1 Germany Krabbe Disease Drugs Market Forecast 10.4.2 France Krabbe Disease Drugs Market Forecast 10.4.3 UK Krabbe Disease Drugs Market Forecast 10.4.4 Italy Krabbe Disease Drugs Market Forecast 10.4.5 Russia Krabbe Disease Drugs Market Forecast 10.5 Middle East & Africa Krabbe Disease Drugs Forecast by Region (2025-2030) 10.5.1 Egypt Krabbe Disease Drugs Market Forecast 10.5.2 South Africa Krabbe Disease Drugs Market Forecast 10.5.3 Israel Krabbe Disease Drugs Market Forecast 10.5.4 Turkey Krabbe Disease Drugs Market Forecast 10.5.5 GCC Countries Krabbe Disease Drugs Market Forecast 10.6 Global Krabbe Disease Drugs Forecast by Type (2025-2030) 10.7 Global Krabbe Disease Drugs Forecast by Application (2025-2030) 11 Key Players Analysis 11.1 GlaxoSmithKline 11.1.1 GlaxoSmithKline Company Information 11.1.2 GlaxoSmithKline Krabbe Disease Drugs Product Offered 11.1.3 GlaxoSmithKline Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.1.4 GlaxoSmithKline Main Business Overview 11.1.5 GlaxoSmithKline Latest Developments 11.2 Johnson & Johnson 11.2.1 Johnson & Johnson Company Information 11.2.2 Johnson & Johnson Krabbe Disease Drugs Product Offered 11.2.3 Johnson & Johnson Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.2.4 Johnson & Johnson Main Business Overview 11.2.5 Johnson & Johnson Latest Developments 11.3 Novartis 11.3.1 Novartis Company Information 11.3.2 Novartis Krabbe Disease Drugs Product Offered 11.3.3 Novartis Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.3.4 Novartis Main Business Overview 11.3.5 Novartis Latest Developments 11.4 Pfizer 11.4.1 Pfizer Company Information 11.4.2 Pfizer Krabbe Disease Drugs Product Offered 11.4.3 Pfizer Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.4.4 Pfizer Main Business Overview 11.4.5 Pfizer Latest Developments 11.5 Sanofi 11.5.1 Sanofi Company Information 11.5.2 Sanofi Krabbe Disease Drugs Product Offered 11.5.3 Sanofi Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.5.4 Sanofi Main Business Overview 11.5.5 Sanofi Latest Developments 11.6 Abbott Laboratories 11.6.1 Abbott Laboratories Company Information 11.6.2 Abbott Laboratories Krabbe Disease Drugs Product Offered 11.6.3 Abbott Laboratories Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.6.4 Abbott Laboratories Main Business Overview 11.6.5 Abbott Laboratories Latest Developments 11.7 Teva Pharmaceutical 11.7.1 Teva Pharmaceutical Company Information 11.7.2 Teva Pharmaceutical Krabbe Disease Drugs Product Offered 11.7.3 Teva Pharmaceutical Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.7.4 Teva Pharmaceutical Main Business Overview 11.7.5 Teva Pharmaceutical Latest Developments 11.8 Takeda 11.8.1 Takeda Company Information 11.8.2 Takeda Krabbe Disease Drugs Product Offered 11.8.3 Takeda Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.8.4 Takeda Main Business Overview 11.8.5 Takeda Latest Developments 11.9 UCB Pharmaceuticals 11.9.1 UCB Pharmaceuticals Company Information 11.9.2 UCB Pharmaceuticals Krabbe Disease Drugs Product Offered 11.9.3 UCB Pharmaceuticals Krabbe Disease Drugs Revenue, Gross Margin and Market Share (2019-2024) 11.9.4 UCB Pharmaceuticals Main Business Overview 11.9.5 UCB Pharmaceuticals Latest Developments 12 Research Findings and Conclusion